Atomwise, leading the charge in artificial intelligence (AI) for drug discovery, is poised to revolutionize the pharmaceutical industry with its innovative approaches. The company has secured a substantial $45 million investment in a series A funding round, spearheaded by Monsanto Growth Ventures, DCVC, and B Capital Group. This funding surge, bringing the company's total capital beyond $51 million, underscores Atomwise's mission to become the go-to AI partner for top pharmaceutical, biotech, and agrochemical firms worldwide. Building on previous support from investors like Y Combinator, Khosla Ventures, and DFJ, the fundi
Like
Comment
Share
